Q Biomed Stock News

Autism Spectrum Disorder Therapeutics Market Key Companies Analyzed in this Report are Otsuka Holdings Co. Ltd. (Tokyo, Japan), Johnson & Johnson Services, Inc. (New Jersey, U.S.), AstraZeneca (Cambridge, U.K.), Pfizer Inc. (New York, U.S.), Allergan (Dublin, Ireland), Q BioMed Inc (New York, U.S.), Hopebridge, LLC. (Indiana, U.S.), Eli Lilly and Company (Indiana, U.S.) Autism Spectrum Disorder Therapeutics Market Key Companies Analyzed in this Report are Otsuka Holdings Co. Ltd. (Tokyo, Japan), Johnson & Johnson Services, Inc. (New Jersey, U.S.), AstraZeneca (Cambridge, U.K.), Pfizer Inc. (New York, U.S.), Allergan (Dublin, Ireland), Q BioMed Inc (New York, U.S.), Hopebridge, LLC. (Indiana, U.S.), Eli Lilly and Company (Indiana, U.S.)

Q BioMed Inc announced it has engaged EVERSANA, the pioneer of next-generation commercial services to the global life sciences industry, to immediately support the commercialization of Strontium89. 

Q BioMed Inc announced that the company closed an additional $2 million funding on October 5 this year, which will be used to support its planned uplisting to Nasdaq and operations for the next 12 mo

Q BioMed Inc announced that the company closed an additional $2 million funding on October 5 this year, which will be used to support its planned uplisting to Nasdaq and operations for the next 12 mo

Q BioMed Inc. has seen an uptick in Strontium89 (Strontium Chloride Sr-89 Injection, USP) sales in its fourth quarter.  As a result, the company said it is projecting its 4Q revenue will likely doubl

NEW YORK, Sept. 28, 2021 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO) a biotech acceleration and commercial stage company focused on licensing and acquiring undervalued biomedical assets in the health

Acquires undervalued biomedical assets to accelerate their development Developing drugs and therapies to treat pediatric nonverbal autism, liver cancer, and glaucoma Produces cancer bone-pain drug Str

Q BioMed Inc said its MAN-19 therapeutic, which it is developing with partner Mannin Research, is poised to start clinical trials in 2022. The MAN-19 therapeutic is a recombinant fusion protein and is

NEW YORK, Sept. 22, 2021 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO) a commercial stage biotechnology acceleration company, is pleased to provide an update on its partner asset MAN-19 for the treatm

Q BioMed Inc said it has received a Notice of Allowance for the patent of its Uttroside B asset in South Korea, adding to the patents already secured in Canada and Japan for the liver cancer chemother

Q BioMed Inc. has recently entered into an exclusive distribution agreement with isoSolutions Marketing & Management Inc., a well-known distributor in Canada providing services and solutions to the nu

Acquires undervalued biomedical assets to accelerate their development Developing drugs and therapies to treat pediatric nonverbal autism, liver cancer, and glaucoma Produces cancer bone-pain drug Str

Q BioMed Inc (OTCQB:QBIO) revealed that it has struck an exclusive license agreement with authorized Europe and Middle East distributor Clionix for the distribution and sales of the company's metastat

Acquires undervalued biomedical assets to accelerate their development Developing drugs and therapies to treat pediatric nonverbal autism, liver cancer, and glaucoma Produces cancer bone-pain drug Str

NEW YORK, May 20, 2021 /PRNewswire/ --  Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech company, announced today that it has hired WSI PBG, LLC (WSI), a Michigan based firm specializing in c